Toll like receptor 5 agonist - Connext
Alternative Names: Advanced entolimod; CNT-101; CNT-102; KMRC011; Korea Medical Radiation Countermeasure 011Latest Information Update: 28 May 2025
At a glance
- Originator Korea Institute of Industrial Technology
- Developer Connext; iNtRON Biotechnology
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Peptides; Radioprotectives
- Mechanism of Action Apoptosis inhibitors; NF-kappa B modulators; Toll-like receptor 5 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Graft-versus-host disease; Stomatitis
Highest Development Phases
- Phase I Graft-versus-host disease; Mucositis; Stomatitis
- Preclinical Cancer
- No development reported Acute radiation syndrome
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Acute-radiation-syndrome(In volunteers) in South Korea (IM, Injection)
- 29 Apr 2024 Phase-I clinical trials in Mucositis (Prevention) (Parenteral) (Connext pipeline; April 2024)
- 27 Nov 2023 Phase-I clinical trials in Stomatitis in South Korea (Parenteral) before November 2023 (Connext Pipeline, November 2023)